The effect of nanoparticles on cellular functions is influenced by their adhesion to cells, uptake by the cells, and subcellular distribution. These processes are strongly dependent on the characteristics of the nanoparticles, such as their material, size, and surface functionality. However, many aspects remain unknown. Despite the approval of some nanomedicines over the past 20 years, their transition from laboratory to clinical treatment has been slow, with many encountering safety issues that lead to their withdrawal.
A major hurdle is the lack of understanding of how nanoparticles interact with cells at the cellular and subcellular levels. Our research focuses on studying the uptake mechanisms, processing, and cellular effects of nanoparticles, specifically in relation to their hepatotoxic potential. While recent studies have observed hepatotoxic effects caused by nanoparticles, these have not been conclusively linked to liver disease, and the underlying mechanisms remain poorly understood. Additionally, the toxic effects on vulnerable livers, such as those with fatty liver disease, fibrosis, or cirrhosis, have been largely ignored in current studies.
By investigating these critical areas, we aim to bridge the knowledge gap and improve the safety and efficacy of nanomedicines in clinical applications.